TRAVIS.A75 is an oil based solution of trenbolone acetate
for IM injection. Trenbolone is an
anabolic steroid with significant anabolic and androgen
effects. The fast acting ester
produces a rapid increase in serum trenbolone levels which
remain elevated for several days
thereafter. Trenbolone promotes significant increases in
strength, muscle anabolism,
appetite, and aggression; and has been demonstrated to
reduce body fat.
Males: Trenbolone use may be indicated in patients where
substantial weight gain and
increases in musculature are required for patient health
after substantial losses of body
mass, especially in instances where caloric intake is
limited and other anabolic therapies
have previously failed. The physician and patient must
consider the risks of therapy versus
the potential benefits.
Anabolic steroids are synthetic derivatives of testosterone.
Certain clinical effects and
adverse reactions demonstrate the androgenic properties of
these drugs. Complete
dissociation of anabolic and androgenic effects has not been
achieved. The actions of
anabolic steroids are thus similar to those of male sex
hormones. Anabolic steroids
suppress the gonadotropic functions of the pituitary and may
exert a direct effect upon the
testes. During exogenous administration of anabolic
androgens, endogenous testosterone
release is inhibited through inhibition of pituitary luteinizing
hormone (LH). At large doses,
spermatogenesis may be suppressed through feedback
inhibition of pituitary folliclestimulating hormone (FSH).
Trenbolone binds strongly to the androgen receptor and its
action is generally considered to
derive therefrom. It produces significant anabolism even
during periods of limited caloric
restriction. The literature offers conicting reports of the
susceptibility of trenbolone to
aromatize into estrogen or reduce to a dihydrotestosterone
derivative. Rat studies have
suggested that trenbolone may exert effects typically
associated with dihydrotestosterone
through a non-DHT pathway potentially with direct receptor
action. It has been suggested
that trenbolone may reduce cortisol production through an
indeterminate pathway of activity
upon glucocorticoid receptors.
Trenbolone has been demonstrated to promote muscle growth,
appetite, aggression, and
the production of red blood cells through the production of
erythropoietic stimulating factor.
Trenbolone is suspected of selective binding of the
progesterone receptor potentially acting
as both an agonist and an antagonist. It has been suggested
that trenbolone is capable of
binding to the prolactin receptor. Thus serum progesterone
and serum prolactin levels
should be monitored during treatment and if elevated
anti-progesterone and anti-prolactin
agents should be considered.
Male: Gynecomastia, excessive frequency and duration of
penile erections, oligospermia.
Skin and Appendages: Hirsutism, male pattern baldness and
Fluid/electrolyte Disturbances: Retention of sodium,
chloride, water, potassium, calcium,
and inorganic phosphates.
Gastrointestinal: Nausea, cholestatic jaundice, alterations
in liver function tests;
hepatocellular neoplasms, peliosis hepatitis, hepatic
adenomas, nephritis, and cholestatic
Hematologic: Suppression of clotting factors II, V, VII,
& X; bleeding in patients on anticoagulant therapy.
Neurological: Increased libido, headache, anxiety,
depression, extreme agitation, irritability,
and generalized paresthesia. Trenbolone may cause severe
Other: Serum lipid changes. hypertension, hypercalcaemia,
priapism, and potentiation of sleep apnea.
Patients on oral anticoagulant therapy require close
monitoring especially when androgens
are started or stopped.
Diabetics: androgens may alter the metabolism of oral
hypoglycemic agents or may change
insulin sensitivity in patients with diabetes mellitus which
may require adjustment of dosage
of insulin and other hypoglycemic drugs.
May alter metabolism of cyclosporins.
Avoid other hepatotoxic medications.
Patients with known hypersensitivity to any ingredients in
Patients with known or suspected carcinomas of the breast,
testis, or prostate.
Patients with severe heart disease, liver disease, or kidney
disease or with a history of
Products containing androgens should not be used in women as
they may cause virilization
and fetal harm.
Women, children and elderly males should not use.
Trenbolone should be used with extreme caution and with the
lowest dosage and duration of
treatment necessary for clinical response pursuant to the
advice of a qualified physician.
Because androgens may alter serum cholesterol concentration,
caution should be used
when administering these drugs to patients with a history of
myocardial infarction or
coronary artery disease.
Trenbolone may increase aggressiveness and cause psychiatric
changes. At the first sign of
psychiatric changes discontinue use of trenbolone and
contact a physician.
Due to its hepatotoxicity, liver functions should be
monitored. Discontinue on signs of
Serum Cholesterol, HDL, LDL, TG. Hemoglobin and Hematocrit,
Hepatic function tests –
Prostatic specific antigen – PSA, Testosterone: total, free,
Dihydrotestosterone & Estradiol
Progesterone, Prolactin, Blood Pressure
Male patients over 40 should undergo a digital rectal
examination and evaluate PSA prior to
androgen use. Periodic evaluations of the prostate should
continue while on androgen
therapy, especially in patients with difficulty in urination
or with changes in voiding habits.
DOSAGE AND ADMINISTRATION
Adult male: 50 – 100mg injected IM every 3 days for duration
limited to 4 weeks under care of
TRAVIS.A75(75mg/ml) – 10 ampules of 1mg/ml each.
|Each ml contains:|
|Trenblone Acetate||75 mg|